Glucagon-Like Peptide-1 Receptor Agonist GLP-1RA Therapy Adherence for Patients with Type 2 Diabetes in a Medicare PopulationReportar como inadecuado




Glucagon-Like Peptide-1 Receptor Agonist GLP-1RA Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Therapy

, Volume 34, Issue 3, pp 658–673

First Online: 11 January 2017Received: 03 November 2016DOI: 10.1007-s12325-016-0470-y

Cite this article as: Nguyen, H., Dufour, R. & Caldwell-Tarr, A. Adv Ther 2017 34: 658. doi:10.1007-s12325-016-0470-y

Abstract

IntroductionAnti-diabetes medication regimen adherence is a clinical challenge in elderly patients with type 2 diabetes T2D and other comorbidities associated with aging. Glucagon-like peptide-1 receptor agonists GLP-1RA therapies such as exenatide once weekly QW, exenatide twice daily BID, and liraglutide once daily QD are an increasingly used class of drugs with proven efficacy and tolerability. Real-world evidence on adherence to GLP-1RAs in elderly or disabled patients is limited. To further the understanding of this drug class, the current study examined medication adherence in Medicare patients aged ≥65 years with T2D initiating a GLP-1RA.

MethodsThis retrospective cohort study used medical and pharmacy claims between 2010 and 2013 for Medicare members in a United States health plan diagnosed with T2D who were new initiators of either exenatide QW n = 537, exenatide BID n = 923, or liraglutide QD n = 3,673. Included patients were between the ages of 65 and 89 and were continuously enrolled for 6 months pre- and post-index. Medication adherence was examined during the post-index period using proportion of days covered PDC ≥80% and ≥90%.

ResultsA significantly higher percentage of patients receiving exenatide QW had a PDC ≥80% 43.2% versus exenatide BID 39.0%, P < 0.01 and liraglutide QD 35.0%, P < 0.001. The patients receiving exenatide QW were significantly more likely to reach a PDC of ≥90% 37.2%, P < 0.001 than those initiating exenatide BID 20.6% or liraglutide QD 23.3%.

ConclusionsWhile results from this retrospective study suggest room for improvement in adherence to GLP-1RAs, medication adherence rates for patients initiating therapy with exenatide QW were higher than patients initiating therapy with exenatide BID or liraglutide QD. Further research is needed to validate these findings in other T2D patient populations.

Funding: AstraZeneca Pharmaceuticals.

KeywordsAdherence Diabetes Exenatide BID Exenatide QW GLP-1RA Liraglutide QD Medicare Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-7D47F0604CA496AA.

Download fulltext PDF



Autor: Hiep Nguyen - Robert Dufour - Amanda Caldwell-Tarr

Fuente: https://link.springer.com/







Documentos relacionados